USPTO approves Acuo Technologies' patent application

NewsGuard 100/100 Score

ACUO TECHNOLOGIES, developers of high-performance medical image management software, data migration tools and services, is pleased to announce that the United States Patent and Trademark Office has approved a patent application for an "Asset Communication Format within a Computer Network." Acuo Technologies is pleased to add the U.S. patent to its portfolio of intellectual property. In general, the granted patent application broadly protects Acuo's technology and use of asset meta information to control routing and storage of digital assets, including medical images, through a medical imaging network. The patent application was originally filed in 2001 and has undergone thorough review by the USPTO prior to being approved. Acuo Technologies values its intellectual property rights and considers them valuable corporate assets. Issuance of the patent is expected by the end of the year.

"This patent truly represents Acuo's engineering excellence and thought leadership in the global image management marketplace," stated Jeff Timbrook, CEO of Acuo Technologies. "This is a comprehensive patent which clearly defines the differentials and advantages in our approach to routing and storing image data sets in a vendor neutral fashion. This patent places Acuo in a unique position and provides us protections of our core technology as we continue to build upon our market leading position in the standards based enterprise archiving space for medical imaging."

Source:

Acuo Technologies

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions